Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tick-borne encephalitis vaccine - Hyland Immuno/Pfizer

Drug Profile

Tick-borne encephalitis vaccine - Hyland Immuno/Pfizer

Alternative Names: FSME-IMMUN Junior; FSME-IMMUN NEW; FSME-IMMUNE; PF-06830414; TBE vaccine - Pfizer; TicoVac; TicoVac Junior

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hyland Immuno
  • Developer Hyland Immuno; Pfizer
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Encephalitis virus infections

Most Recent Events

  • 21 Feb 2022 Pfizer completes a phase III trial in Encephalitis virus infections (In infants, In children, In adolescents, In adults, In the elderly, Prevention) in Japan (IM) (NCT04648241)
  • 13 Aug 2021 Registered for Encephalitis virus infections (In children, In infants, In adolescents, In adults, In the elderly, Prevention) in USA (IV)
  • 23 Feb 2021 FDA assigns PDUFA action date of (31/08/2021) for tick-borne encephalitis vaccine for Encephalitis virus infections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top